Clinical trials: Ticagrelor
Acute Coronary Syndrome
Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With STEMI Undergoing Primary PCI
Therefore, in this study, we try to evaluate the impact of clopidogrel loading dose 300mg vs. ticagrelor 180 mg on myocardial injury as measured by contrast-enhanced magnetic resonance imaging (CE-MRI) in STEMI patients…
- Trial name
- NCT02792712
- Testing
- Ticagrelor, Clopidogrel
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Pharmacodynamics
Clopidogrel And Ticagrelor in Healthy Subjects
To evaluate the pharmacodynamics of a lower Ticagrelor dose in healthy Korean volunteers compared with standard Clopidogrel agent.
- Trial name
- NCT02086903
- Testing
- Ticagrelor 90 mg, Clopidogrel 600 mg
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dong-A University
Coronary Artery Disease
Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Assess the pharmacodynamic effect of ticagrelor vs. Clopidogrel in American Indian patients with stable coronary artery disease.
- Trial name
- NCT01706510
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Rapid City Regional Hospital, Inc
ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction
Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction
The purpose of the IMPRESSION study is to determine whether intravenous administration of morphine prior to ticagrelor administration in ST-segment elevation myocardial infarction (STEMI) patients and in non-ST-segment elevation…
- Conditions
- ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction, VA Drug Interactions
- Trial name
- IMPRESSION (NCT02217878)
- Testing
- Morphine, Ticagrelor
- Where
- Poland
- Volunteers
- 74 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Ischemic Stroke
Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke
Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through…
- Trial name
- NCT06202755
- Testing
- Ticagrelor 90 MG, Cilostazol 100 MG
- Where
- Egypt
- Volunteers
- 580 people
- Sponsor
- Kafrelsheikh University
Ischemia
The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males
To test the effect of atorvastatin or placebo in combination with ticagrelor on ACh-induced vasodilatation of the forearm resistance vasculature as assessed by forearm blood flow (FBF) measurement before and 10 min after a 20 min…
- Trial name
- NCT02910778
- Testing
- Atorvastatin, Ticagrelor
- Where
- Austria
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Non-ST Elevation Acute Coronary Syndrome
Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.
The purpose of this study is to determine if ticagrelor is as effective as clopidogrel in rate of onset and degree of platelet inhibition for patients with non-ST elevation of acute coronary syndrome (NSTE-ACS) undergoing ad hoc…
- Trial name
- NSTE-ACS (NCT02052635)
- Testing
- ticagrelor, clopidogrel
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
STEMI, Morphine
Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients
This study will examine the impact of the peripheral opioid antagonist methylnaltrexone on the onset of effect of ticagrelor in morphine treated patients with ST elevation myocardial infarction (STEMI).
- Conditions
- STEMI, Morphine, Ticagrelor, Methylnaltrexone
- Trial name
- MOVEMENT (NCT02942550)
- Testing
- Methylnaltrexone bromide (Relistor®)., Sodium Chloride 9mg/mL
- Where
- 2 sites in Sweden
- Volunteers
- 82 people
- Sponsor
- Karolinska University Hospital
Acute Coronary Syndrome, Acute Myocardial Infarction
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome
The objective of the study is to establish a de-scaling strategy of P2Y12 inhibitors (P2Y12 i) with a decrease in hemorrhagic events without increasing ischemic complications based on a Platelet Function Test (PFT).
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- VERONICA (NCT04654052)
- Testing
- Clopidogrel, Previous treatment
- Where
- 19 sites in Spain
- Volunteers
- 637 people
- Sponsor
- Fundación EPIC
PCI, Coronary Stents
Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor
When ticagrelor should be discontinued prior to elective surgery is unclear. The risks of bleeding when it is continued peri-operatively have to be weighed against the risk of coronary artery thrombosis when stopped.
- Trial name
- BRILIQUE (NCT02297971)
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Örebro University, Sweden
Acute Coronary Syndrome, STEMI
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS
Elderly individuals are increasingly represented among patients with acute coronary syndrome (ACS). Dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 receptor inhibitor has an established role in the prevention of…
- Conditions
- Acute Coronary Syndrome, STEMI, NSTEMI, Coronary Artery Disease
- Trial name
- PlinytheElder (NCT04739384)
- Testing
- Ticagrelor 90mg, Ticagrelor 60 mg
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Federico II University
Antiplatelet Drug, Acute Coronary Syndrome
1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon
Drug-Coated Balloon (DCB) angioplasty is similar to plain old balloon angioplasty procedurally, but there is an anti-proliferative medication paclitaxel coated to the balloon.
- Conditions
- Antiplatelet Drug, Acute Coronary Syndrome, Angioplasty, Balloon
- Trial name
- CAGEFREEII (NCT04971356)
- Testing
- Aspirin 100mg for 1-month (immediately after PCI), Ticagrelor 90mg for 6-month (immediately after PCI), Aspirin 100mg for 6-month (6-month post PCI)
- Where
- China
- Volunteers
- 1,948 people
- Sponsor
- Xijing Hospital
ST-segment Elevation Myocardial Infarction
Rapid Activity of Platelet Inhibitor Drugs Study
The aim of the RAPID study is to assess the rapid onset of action of the 2 novel oral antiplatelet agents, Prasugrel and Ticagrelor, in 50 patients with STEMI undergoing PPCI with bivalirudin monotherapy.
- Trial name
- RAPID (NCT01510171)
- Testing
- Prasugrel, Ticagrelor
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Careggi Hospital
Acute Myocardial Infarction
Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Prospective, randomized, open-label, single-center, investigator-initiated trial, including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) within 12…
- Trial name
- PERSEUS (NCT02531165)
- Testing
- Fentanyl, Morphine, Ticagrelor
- Where
- Switzerland
- Volunteers
- 38 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Coronary Artery Disease, Acute Coronary Syndrome
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class cyclopentyltriazolopyrimidine (CPTP).
- Trial name
- SWAP3 (NCT02016170)
- Testing
- Ticagrelor 180mg, Prasugrel 10mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Florida
Healthy Subjects
Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg
The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose.
- Trial name
- TIC-025-23 (NCT06233266)
- Testing
- Ticagrelor-Test product, Ticagrelor-Reference product
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bio-innova Co., Ltd
Coronary Artery Disease
Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease
Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS).
- Trial name
- NCT02514642
- Testing
- low-dose ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Healthy Volunteer
Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers
This is a non-randomized, open-label, fixed-sequence drug-drug interaction study to evaluate the effects of itraconazole and ticagrelor on the pharmacokinetics of catequentinib hydrochloride (AL3818) in healthy volunteers.
- Trial name
- NCT07438886
- Testing
- AL3818 Capsule, Itraconazole capsule, Ticagrelor Tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Advenchen Laboratories Nanjing Ltd.
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
The primary objective of this study is to assess the pharmacodynamic (PD) effects of clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.) dose of ACT-246475 in healthy male and female…
- Trial name
- NCT03430661
- Testing
- ACT-246475, Clopidogrel, Prasugrel
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Viatris Innovation GmbH